since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
Company profile
Ticker
VXRT
Exchange
Website
CEO
Andrei Floroiu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC
SEC CIK
Corporate docs
Subsidiaries
Vaxart Biosciences, Inc. • Biota Holdings • Biota Scientific Management Pty, Ltd. ...
IRS number
591212264
VXRT stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 24
8-K
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
6 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Other Events
15 Feb 24
8-K/A
Departure of Directors or Certain Officers
2 Feb 24
8-K
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
8-K
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
16 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.24 mm | 33.24 mm | 33.24 mm | 33.24 mm | 33.24 mm | 33.24 mm |
Cash burn (monthly) | 3.35 mm | 1.46 mm | 5.94 mm | 8.13 mm | 5.00 mm | 7.17 mm |
Cash used (since last report) | 19.92 mm | 8.70 mm | 35.37 mm | 48.42 mm | 29.77 mm | 42.71 mm |
Cash remaining | 13.31 mm | 24.54 mm | -2.13 mm | -15.18 mm | 3.47 mm | -9.48 mm |
Runway (months of cash) | 4.0 | 16.8 | -0.4 | -1.9 | 0.7 | -1.3 |
Institutional ownership, Q3 2023
10.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 95 |
Opened positions | 12 |
Closed positions | 23 |
Increased positions | 19 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 13.86 bn |
Total shares | 18.46 mm |
Total puts | 19.40 k |
Total calls | 268.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 6.96 mm | $5.25 bn |
Cantor Fitzgerald, L. P. | 1.81 mm | $1.36 bn |
BLK Blackrock | 1.79 mm | $1.35 bn |
Geode Capital Management | 1.79 mm | $1.35 bn |
Millennium Management | 1.58 mm | $1.19 bn |
STT State Street | 466.55 k | $351.78 mm |
MS Morgan Stanley | 411.10 k | $309.97 mm |
Charles Schwab Investment Management | 314.82 k | $237.38 mm |
Gsa Capital Partners | 282.94 k | $213.55 mm |
Cubist Systematic Strategies | 274.17 k | $206.72 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Lo Steven | Common Stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 250,000 |
18 Mar 24 | Lo Steven | Stock Option Common Stock | Grant | Acquire A | No | No | 1.16 | 1,000,000 | 1.16 mm | 1,000,000 |
18 Mar 24 | Phillip E Lee | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 241,808 |
18 Mar 24 | Phillip E Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 1.16 | 410,000 | 475.60 k | 410,000 |
18 Mar 24 | James F. Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 330,093 |
18 Mar 24 | James F. Cummings | Stock Option Common Stock | Grant | Acquire A | No | No | 1.16 | 410,000 | 475.60 k | 410,000 |
18 Mar 24 | Edward B Berg | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 270,706 |
18 Mar 24 | Edward B Berg | Stock Option Common Stock | Grant | Acquire A | No | No | 1.16 | 410,000 | 475.60 k | 410,000 |
2 Feb 24 | James F. Cummings | Common Stock | Payment of exercise | Dispose F | No | No | 1.2 | 7,965 | 9.56 k | 240,093 |
2 Feb 24 | Edward B Berg | Common Stock | Payment of exercise | Dispose F | No | No | 1.2 | 9,220 | 11.06 k | 180,706 |
News
Recap: Vaxart Q4 Earnings
14 Mar 24
Vaxart Q4 2023 GAAP EPS $(0.12) Beats $(0.14) Estimate, Sales $3.245M Beat $1.250M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Vaxart's Earnings: A Preview
13 Mar 24
Vaxart Announces Publication In Vaccines Of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal And Systemic Immunogenicity And Reduce Viral Shedding After SARS-CoV-2 Challenge
5 Feb 24
Press releases
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 Mar 24
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 24
Thinking about buying stock in Cano Health, Vaxart, Macy's, Albemarle Corp, or BioXcel Therapeutics?
5 Feb 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19 Jan 24